Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035))

  1. Rondeau, E.
  2. Scully, M.
  3. Ariceta, G.
  4. Barbour, T.
  5. Cataland, S.
  6. Heyne, N.
  7. Miyakawa, Y.
  8. Ortiz, S.
  9. Swenson, E.
  10. Vallee, M.
  11. Yoon, S.-S.
  12. Kavanagh, D.
  13. Haller, H.
  14. Babu, S.
  15. Broeders, N.
  16. Lietar, N.
  17. Brown, F.
  18. Campbell, P.
  19. Campistol, J.M.
  20. Blasco, M.
  21. Chowdhury, P.
  22. Kasimatis, T.
  23. Cirami, L.
  24. Caroti, L.
  25. Antognoli, G.
  26. Delmas, Y.
  27. Dobronravov, V.
  28. Gaeckler, A.
  29. Garrouste, C.
  30. Greenwood, G.
  31. Griffin, S.
  32. Huang, C.-C.
  33. Chen, I.-R.
  34. Huang, S.
  35. Kim, J.S.
  36. La Manna, G.
  37. Comai, G.
  38. Cappuccilli, M.
  39. Le Quintrec, M.
  40. Jeantet, G.
  41. Fumie, I.
  42. Luque, Y.
  43. Menne, J.
  44. Morelle, J.
  45. Goffin, E.
  46. Muhlfeld, A.
  47. Nagaraj, S.
  48. Arepally, G.
  49. Oh, D.
  50. Okumi, M.
  51. Terente, M.P.
  52. Gutierréz, E.
  53. Rodriguez, P.
  54. Provot, F.
  55. Schönermarck, U.
  56. Fischereder, M.
  57. Terrada, N.R.
  58. Seitz-Polski, B.
  59. Favre, G.
  60. Boyer-Suavet, S.
  61. Vinogradova, M.
  62. Kirsanova, T.
  63. Wong, E.K.S.
  64. Mostrar todos los/as autores/as +
Revista:
Kidney International

ISSN: 1523-1755,  0085-2538

Año de publicación: 2021

Volumen: 99

Número: 5

Páginas: 1244

Tipo: Errata

DOI: 10.1016/J.KINT.2021.03.008 GOOGLE SCHOLAR lock_openAcceso abierto editor
Fuente de los datos: Scopus